Business
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
FEATURED STORIES
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
This week the pharma giant announced a second collaboration agreement with Connecticut-based Arvinas to develop and commercialize its PROTAC estrogen receptor protein degrader.
Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.
More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.
Shares of Arcus Biosciences dipped sharply in post-market trading Monday after it was learned that the company’s chief medical officer was departing for a role at Gilead Sciences.
The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science.
Rivus’ CMAs are designed to overcome these illnesses by activating the body’s natural process of mitochondrial uncoupling.
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
Regeneron continues to expand its presence in New York. Over the next six years, the company will invest approximately $1.8 billion to expand its Tarrytown facilities. The investment will support the addition of 1,000 new jobs.